The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the erspc risk calculator for prostate cancer in prescreened men Academic Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Early Detection of Cancer
  • Kallikreins
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • We studied the added value of novel biomarkers to previously developed risk prediction models for prostate cancer. We found that inclusion of these biomarkers resulted in an increase in predictive ability.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4407822

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2014.08.011

PubMed ID

  • 25168616

Additional Document Info

start page

  • 1109

end page

  • 15

volume

  • 66

number

  • 6